Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Microbix Biosystems Inc T.MBX

Alternate Symbol(s):  MBXBF

Microbix Biosystems Inc. develops and commercializes biological and technological solutions for human health and wellbeing. It enables the commercialization of diagnostic assays by making a range of critical ingredients and devices for the global diagnostics industry, notably antigens for immunoassays and its laboratory quality assessment products (QAPs) that support clinical lab proficiency testing, enable assay development and validation, or help ensure the quality of clinical diagnostic workflows. Its segments include development, manufacturing and sales of products relating to the medical diagnostics industry, namely antigens as test ingredients, quality assessment products to help ensure the accuracy of test workflows and viral transport medium to enable collection of patient test samples and, and development and commercialization of novel and proprietary products or technologies, such as Kinlytic. Its Kinlytic urokinase is a biologic thrombolytic drug used to treat blood clots.


TSX:MBX - Post by User

Comment by Mbxwatcheron Aug 11, 2022 12:17pm
141 Views
Post# 34888603

RE:Q-3

RE:Q-3Encouraging that a "vanilla" quarter spun off 2m in cash though.

14m in cash while just about to ramp up QAP's.  A few more deals like the one announced yesterday, and I think we may have just reported our last plain quarter....

As a long time holder of this, who suffered countless dilutive financings, (along with all of you of course), that cash number brings great comfort, as we march along into a new era of Health care as what I think is something of a cutting edge company.

Neither thrilled nor surprised by Q3, but very happy to see the companies investments begin to pay off.......Now an announcement on VTM to someone other than Ontario, and we are off to the races I think.



<< Previous
Bullboard Posts
Next >>